ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain.
about
Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure.Emerging biomarkers in heart failure and cardiac cachexiaSoluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community-Dwelling PopulationComparison Between Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emergency Department With Chest Pain.The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2.Clinical use of novel biomarkers in heart failure: towards personalized medicine.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers.Clinical relevance of sST2 in cardiac diseases.The current status of heart failure diagnostic biomarkers.Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD.Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population.Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins.Temporal changes of soluble ST2 after cardiovascular interventions.Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.Clinical roles of soluble ST2 for the outcomes of cardiac valve operationsPrognostic value of plasma ST2 in patients with non-ST segment elevation acute coronary syndrome.
P2860
Q30386714-E391DDC1-C916-4A65-BC65-2ED848EC6F98Q34836097-72DA7123-82C7-4E5C-8A8D-B2BB245AA66EQ37240346-D622AC2D-1246-4632-9A16-C1904B8A2339Q37547780-93731AF9-1D62-4B6F-BCF7-D4DB026D925FQ38068933-15A53355-AA78-4377-A4BE-FB4B8976C9D2Q38109588-317917CE-1544-42A9-80D5-184A873C243BQ38154222-3487B9D6-252D-4215-8A97-90D3BC08F0A0Q38177341-13E9128B-7002-458C-ABFD-96EE1F2C9A07Q38626970-8A51FE16-7315-43A0-B67D-B625D0C29AB0Q38703882-04885611-F11C-45C7-A70D-62879F7A9750Q38709053-43637BE1-AE2F-4D2F-A603-D86CAEED6949Q38714511-E7C829E3-83BC-4A04-8DF3-C18055BB1C1BQ39185614-A7566203-982D-4DF5-B668-F1367EAE69C6Q39507885-A248880C-8827-4E63-BDC0-4EB0D1B923AFQ40297133-F423D70A-6BA6-4F40-AF56-D547730A5FC1Q55094584-0338EF3E-7915-4148-97A5-C97A24C10653Q55357138-5887CF28-4E12-498D-A9DD-3902D4DA0410
P2860
ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
ST2 has diagnostic and prognos ...... cy department with chest pain.
@en
ST2 has diagnostic and prognos ...... cy department with chest pain.
@nl
type
label
ST2 has diagnostic and prognos ...... cy department with chest pain.
@en
ST2 has diagnostic and prognos ...... cy department with chest pain.
@nl
prefLabel
ST2 has diagnostic and prognos ...... cy department with chest pain.
@en
ST2 has diagnostic and prognos ...... cy department with chest pain.
@nl
P2093
P1476
ST2 has diagnostic and prognos ...... ncy department with chest pain
@en
P2093
A Mark Richards
Martin Than
Sally J Aldous
P304
P356
10.1016/J.CARDFAIL.2012.01.008
P577
2012-02-02T00:00:00Z